Ophthotech Corp (OPHT)

4.72
0.14 2.88
NASDAQ : Health Care
Prev Close 4.86
Open 4.81
Day Low/High 4.70 / 4.97
52 Wk Low/High 35.72 / 80.00
Volume 1.51M
Avg Volume 2.79M
Exchange NASDAQ
Shares Outstanding 35.70M
Market Cap 173.49M
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Learn to Shift Gears in Your Trading

Learn to Shift Gears in Your Trading

When you seek to find the right structure or combination, you can get hurt.

Dow Posts Another Record Close but Nasdaq Slips Amid Tech Declines

Dow Posts Another Record Close but Nasdaq Slips Amid Tech Declines

The Dow posts a record close with the S&P 500 lower, while tech stocks dragged on the Nasdaq as Wall Street looks to a Fed decision on interest rates Tuesday.

Dow Sets Record as Oil Settles Higher but Nasdaq Slips Amid Tech Declines

Dow Sets Record as Oil Settles Higher but Nasdaq Slips Amid Tech Declines

The Dow rises but pares gains as Wall Street looks to a Fed decision on interest rates later in the week.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of An Investigation Involving Possible Securities Fraud Violations By Ophthotech Corporation And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of An Investigation Involving Possible Securities Fraud Violations By Ophthotech Corporation And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Ophthotech Corporation ("Ophthotech" or the "Company") (NASDAQ:OPHT) concerning possible violations of federal securities laws by the Company...

How to Trade Monday's Most Active Stocks - AMD, CBS, Ophthotech and More

How to Trade Monday's Most Active Stocks - AMD, CBS, Ophthotech and More

Here's a technical look on how to trade some of the most active stocks on the market this week.

Oversold Conditions For Ophthotech (OPHT)

Oversold Conditions For Ophthotech (OPHT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Dow Hits Record, Gets Lift From Energy Sector as Oil Prices Surge

Dow Hits Record, Gets Lift From Energy Sector as Oil Prices Surge

Stocks are mixed Monday as oil prices surge after non-OPEC countries agree to cut production and markets anticipate Fed moves.

Ophthotech Plunges on Eye-Drug-Study Failure

Ophthotech Plunges on Eye-Drug-Study Failure

Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.

Jim Cramer -- Ophthotech's Loss a Cautionary Win for Regeneron

Jim Cramer -- Ophthotech's Loss a Cautionary Win for Regeneron

Shares of Ophthotech are plunging after the company's Phase 3 results failed to meet specific endpoints.

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

Ophthotech Announces Results From Pivotal Phase 3 Trials Of Fovista® In Wet Age-Related Macular Degeneration

Ophthotech Announces Results From Pivotal Phase 3 Trials Of Fovista® In Wet Age-Related Macular Degeneration

Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating...

January 2019 Options Now Available For Ophthotech (OPHT)

January 2019 Options Now Available For Ophthotech (OPHT)

Investors in Ophthotech Corp saw new options become available today, for the January 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ophthotech Reports Third Quarter 2016 Financial And Operating Results

Ophthotech Reports Third Quarter 2016 Financial And Operating Results

Ophthotech Corporation (Nasdaq: OPHT) today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company's business and product development programs.

Ophthotech Announces The Publication Of Fovista® In Combination With Lucentis® Phase 2b Study Results In Ophthalmology®, The Journal Of The American Academy Of Ophthalmology

Ophthotech Announces The Publication Of Fovista® In Combination With Lucentis® Phase 2b Study Results In Ophthalmology®, The Journal Of The American Academy Of Ophthalmology

Ophthotech Corporation (Nasdaq:OPHT) today announced that the Phase 2b study results of Fovista ® (pegpleranib), the Company's anti-PDGF agent administered in combination with Lucentis ® (ranibizumab) anti-VEGF...

Ophthotech Corporation To Report Third Quarter 2016 Financial Results And Host Conference Call On Tuesday, November 8, 2016

Ophthotech Corporation To Report Third Quarter 2016 Financial Results And Host Conference Call On Tuesday, November 8, 2016

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter financial results on Tuesday, November 8, 2016.

'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?

'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?

Jim Cramer says he likes LUV and UAL, but JBLU is not a favorite.

Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track

Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track

Don't ignore a big shift for American Express and don't dig in your heels, says Jim Cramer.

Ophthotech Corporation To Present At The Morgan Stanley Global Healthcare Conference

Ophthotech Corporation To Present At The Morgan Stanley Global Healthcare Conference

Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.

Insider Trading Alert - OPHT, MXIM And JBLU Traded By Insiders

Insider Trading Alert - OPHT, MXIM And JBLU Traded By Insiders

Stocks with insider trader activity include OPHT, MXIM and JBLU

Ophthotech Reports Second Quarter 2016 Financial And Operating Results

Ophthotech Reports Second Quarter 2016 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the second quarter ended June 30, 2016 and provided an update on the Company's business and product development programs.

Ophthotech Announces Election Of Ian F. Smith, Vertex Executive Vice President And Chief Financial Officer, To Its Board Of Directors

Ophthotech Announces Election Of Ian F. Smith, Vertex Executive Vice President And Chief Financial Officer, To Its Board Of Directors

Ophthotech Corporation (Nasdaq:OPHT) today announced the election of Ian F.

Short Interest Moves 17% Higher For OPHT

Short Interest Moves 17% Higher For OPHT

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 434,231 share increase in total short interest for Ophthotech Corp , to 2,977,494, an increase of 17.07% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ophthotech Corporation To Report Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016

Ophthotech Corporation To Report Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016

Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2016 financial results on Wednesday, August 3, 2016.

These 4 Stocks Are Poised for Breakout Profits

These 4 Stocks Are Poised for Breakout Profits

Positive momentum and money flow set the stage for higher prices in these four stocks.

Ophthotech Completes Patient Recruitment In Phase 3 Trial Of Fovista® Anti-PDGF Therapy In Combination With Eylea® Or Avastin® In Wet Age-Related Macular Degeneration

Ophthotech Completes Patient Recruitment In Phase 3 Trial Of Fovista® Anti-PDGF Therapy In Combination With Eylea® Or Avastin® In Wet Age-Related Macular Degeneration

Ophthotech Corporation (Nasdaq: OPHT) today announced the completion of patient recruitment in its Phase 3 trial of Fovista ® (pegpleranib), anti-PDGF therapy, in combination with Eylea ® (aflibercept) or...

Insider Trading Alert - OPHT, MMS And MLNX Traded By Insiders

Insider Trading Alert - OPHT, MMS And MLNX Traded By Insiders

Stocks with insider trader activity include OPHT, MMS and MLNX

Stock To Watch: Ophthotech (OPHT) In Perilous Reversal

Stock To Watch: Ophthotech (OPHT) In Perilous Reversal

Trade-Ideas LLC identified Ophthotech (OPHT) as a "perilous reversal" (up big yesterday but down big today) candidate